Rapid Onset of Antidepressant Action: A New Paradigm in the Research and Treatment of Major Depressive Disorder
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 150 of the 150 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Current therapeutics of depression are similar in their time to antidepressant action and often take weeks to months to achieve response and remission, which commonly results in considerable morbidity and disruption in personal, professional, family, and social life, as well as risk for suicidal behavior. Thus, treatment strategies presenting a rapid improvement of depressive symptoms--within hours or even a few days--and whose effects are sustained would have an enormous impact on public health. This article reviews the published data related to different aspects of rapid improvement of depressive symptoms. DATA SOURCES: Literature for this review was obtained through a search of the MEDLINE database (1966-2007) using the following keywords and phrases: rapid response, antidepressant, time to, glutamate, sleep, therapeutics, latency, and depression. The data obtained were organized according to the following topics: clinical relevance and time course of antidepressant action, interventions showing evidence of rapid response and its potential neurobiological basis, and new technologies for better understanding rapid anti-depressant actions. DATA SYNTHESIS: A limited number of prospective studies evaluating rapid antidepressant actions have been conducted. Currently, only a few interventions have been shown to produce antidepressant response in hours or a few days. The neurobiological basis of these rapid antidepressant actions is only now being deciphered. CONCLUSIONS: Certain experimental treatments can produce antidepressant response in a much shorter period of time than existing medications. Understanding the molecular basis of these experimental interventions is likely to lead to the development of improved therapeutics rather than simply furthering our knowledge of current standard antidepressants.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, the definition as well the optimal method and time-frame to evaluate rapid antidepressant actions have varied across the literature, without clear consensus (1).”
From Total Sleep Deprivation Followed by Bright Light Therapy as Rapid Relief for Depression: A Pragmatic Randomized Controlled Trial (2021) · cites this paper as [1]
Citations
Cites
Bliss, T. V. P., & Gardner‐Medwin, A. R. (1973) · The Journal of Physiology · doi:10.1113/jphysiol.1973.sp010274 · Cited by 7,437
Deep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationThe functioning and well-being of depressed patients. Results from the Medical Outcomes Study
Wells, K. B. (1989) · JAMA · doi:10.1001/jama.262.7.914 · Cited by 2,808
Sleep function and synaptic homeostasis
Tononi, G., & Cirelli, C. (2006) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2005.05.002 · Cited by 2,151
The Functioning and Well-being of Depressed Patients: Results From the Medical Outcomes Study
Wells, K. B. (1989) · JAMA · doi:10.1001/jama.1989.03430070062031 · Cited by 2,130
Hippocampal atrophy in recurrent major depression
Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G., & Vannier, M. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3908 · Cited by 1,932
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03251.2002 · Cited by 1,654
Cited by
Items 101–196 of 196
Suicidal Ideation during Antidepressant Treatment: Do Genetic Predictors Exist?
Perroud, N. A. (2011) · CNS Drugs · doi:10.2165/11589420-000000000-00000 · Cited by 25
“Higher risk in the early phase of treatment has been linked to initial increases in energy while mood is still depressed.([9-11]) In addition, antidepressant adverse effects such as akathisia, induced mixed affective state and the more complex ‘activation syndrome’ (including, in addition to akathisia, symptoms such a…”
BackgroundBaune, B. T., Florea, I., Ebert, B., Touya, M., Ettrup, A., Hadi, M., & Ren, H. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s325954 · Cited by 26
“The most commonly prescribed antidepressants received by study participants within the past 2 years were bupropion, escitalopram, and sertraline (all reported by over one-third of participants); these antidepressants generally take several weeks to achieve their full therapeutic effects.(56) These findings suggest a n…”
BackgroundMeltzer-Brody, S. E., Gerbasi, M. E., Mak, C., Toubouti, Y. M., Smith, S. C., Roskell, N., TAN, R. S.-H., Chen, S., & Deligiannidis, K. M. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2334160 · Cited by 34
“Given that SSRIs may take 6–12 weeks for some patients to experience effects 62,75 , such interpolation likely overestimated their potential effects in the early treatment course and likely provides a conservative estimate of the relative effect of zurano-lone compared to other treatments at early…”
Albert, U., Lamba, P., & Stahl, S. M. (2021) · CNS Spectrums · doi:10.1017/s1092852921000304 · Cited by 21
“This lag in antidepressant action may have negative consequences, such as increased risk of suicide attempts (presumably due to a mismatch in patients’ improvement of symptoms; their lack of energy may be resolved while they are still depressed with negative thoughts), psychosocial dysfunction, and poor quality of lif…”
BackgroundThe network analysis of depressive symptoms before and after two weeks of antidepressant treatment
Zhou, J. L., Liu, S., Mayes, T. L., Feng, Y., Fang, M., Xiao, L., & Wang, G. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.11.059 · Cited by 25
Li, Z., Wu, Q., Peng, P., Wu, M., Liu, S., & Liu, T. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115640 · Cited by 26
Grossert, A., Mehrjardi, N. Z., Bailey, S., Lindsay, M. A., Hescheler, J., Šarić, T., & Teusch, N. E. (2019) · Cells · doi:10.3390/cells8101139 · Cited by 21
Patel, T. K., Patel, V. B., & Rana, D. G. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.04.018 · Cited by 21
Aruhan, Gong, Q., Tuo, Y.-J., Zhai, S.-T., He, B., Zou, E.-G., Wang, M., Huang, T.-Y., Zha, C.-L., He, M., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119274 · Cited by 22
Paterson, N. E., Balcı, F., Campbell, U. C., Olivier, B., & Hanania, T. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110364272 · Cited by 19
“Specifically, there is a high proportion of non-responsive patients (Souery et al., 1999); a latency of therapeutic onset of weeks to months (Machado-Vieira et al., 2008); and a high prevalence of sexual side-effects (for review, see Rosen et al., 1999).”
BackgroundTreating depression in clinical practice: new insights on the multidisciplinary use of trazodone
Albert, U., Tomasetti, C., Marra, C., Neviani, F., Pirani, A., Taddeo, D., Zanetti, O. O., & Maina, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1207621 · Cited by 20
Clinical Efficacy of Ketamine for Treatment-resistant Depression
Bratsos, S., & Saleh, S. N. (2019) · Cureus · doi:10.7759/cureus.5189 · Cited by 24
Efficacy of Ketamine in bipolar depression: focus on anhedonia.
Gałuszko‐Węgielnik, M., Wiglusz, M. S., Słupski, J., Szałach, Ł. P., Włodarczk, A., Górska, N., Szarmach, J., Jakuszkowiak‐Wojten, K., Wilkowska, A., & Cubała, W. J. (2019) · PubMed · Cited by 20
Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?
Fornaro, M., Aguglia, E., Dell’Osso, L., & Perugi, G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.632366 · Cited by 17
“This accounts for increased morbidity and lower compliance with medication [40,41].”
BackgroundLv, D., Chen, Y., Shen, M., Liu, X., Zhang, Y., Xu, J., & Wang, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.046 · Cited by 19
Vieta, E., Florea, I., Schmidt, S. N., Areberg, J., & Ettrup, A. (2019) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000271 · Cited by 16
Bjartmar, L., Alkhori, L., Ruud, J., Mohammed, A. H. S., Marcusson, J. O., & Hallbeck, M. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.004 · Cited by 16
Luckenbaugh, D. A., Ameli, R., Brutsché, N. E., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.12.015 · Cited by 16
“The subscale fromMaier and Philipp (1985), however, showed somewhat less sensitivity to response relative to the total score than the other subscales.”
BackgroundSelf-citationGraham, B., Garcia, N. M., Burton, M. S., Cooper, A. A., Roy‐Byrne, P., MAVISSAKALIAN, M. R., Feeny, N. C., & Zoellner, L. A. (2018) · The British Journal of Psychiatry · doi:10.1192/bjp.2018.211 · Cited by 16
Does early improvement in major depression protect against treatment emergent suicidal ideation?
Seemüller, F., Schennach-Wolff, R., Obermeier, M., Henkel, V., Möller, H. J., & Riedel, M. J. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.10.010 · Cited by 15
Falkowska, M., Ntamati, N. R., Nevian, N. E., Nevian, T., & Acuña, M. A. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1139205 · Cited by 17
“Tricyclic antidepressants (TCAs) and serotonin / norepinephrine reuptake inhibitors (SNRIs) are among the most widely used treatments for chronic pain and pain-related depression, but a variety of side-effects and time-limiting factors constrain their use (Mico et al., 2006; Trivedi et al., 2006; Machado-Vieira et al.…”
BackgroundWade, A. G., Crawford, G. M., Nemeroff, C. B., Schatzberg, A. F., Schlaepfer, T. E., McConnachie, A., Haazen, L., & Buntinx, E. (2011) · Psychological Medicine · doi:10.1017/s0033291711000158 · Cited by 14
“The delay in efficacy seen with current therapies is likely to contribute to poor compliance and early treatment discontinuation (Machado-Vieira et al. 2008).”
BackgroundChen, H., Lin, Q., Lin, T., Lin, Y., Lin, X., Chen, R., Luo, L., Lin, F., & Xiao, Y. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.04.024 · Cited by 15
Ioannou, M., Szabó, Z., Widmark-Jensen, M., Vyrinis, G., Karlsson, C., & Steingrimsson, S. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.705090 · Cited by 13
Li, G., Liu, T., Kong, X., Wang, L., & Jin, X. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0254-2 · Cited by 15
Иванов, С. В., & Samushiya, M. A. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s58994 · Cited by 14
“Relatively slow onset of efficacy has been identified as an important limitation of most current antidepressant drugs.(24,25) Perceived improvement early in treatment may be important in maintaining patient confidence in the prescribed treatment, leading to greater adherence and persistence with treatment and improved…”
Pandey, D., Bhatt, S., Jindal, A., & Gautam, B. (2014) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.144935 · Cited by 17
“[24] It is a notable finding that the antidepressant-like effects of the co-administration of ESC and KET were evident with a short course of treatment (7 days) in OBX rats.”
Rancāns, E., Zámbori, J., Dalsgaard, M. K., Baayen, C., Areberg, J., Ettrup, A., & Florea, I. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000326 · Cited by 13
“While most of the currently available treatments may require several weeks to induce clinically relevant symptomatic improvement (Machado-Vieira et al., 2008), a number of new compounds with fast-acting properties are being developed, including the recently approved adjunctive intranasal esketamine for treatment-resis…”
BackgroundMolero, P., Ibáñez, Á., de Diego-Adeliño, J., Ramos‐Quiroga, J. A., Dorado, M. G., Rengel, P. M. L., & Sáiz, P. A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03149-z · Cited by 15
Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review
FREIND, J. M. K., Beserra, F. R., Menezes, B. S., & Mograbi, D. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2248989 · Cited by 13
“For instance, these medications can take weeks to reach their full therapeutic effects while patients are vulnerable to a higher risk of self-harm and other devastating symptoms (Machado-Vieira et al. 2008).”
Chronic venlafaxine treatment fails to alter the levels of galanin system transcripts in normal rats
Petschner, P., Juhász, G., Tamási, V., Ádori, C., Tóthfalusi, L., Hökfelt, T. G. M., & Bagdy, G. (2016) · Neuropeptides · doi:10.1016/j.npep.2016.01.010 · Cited by 13
“, 2006) and they have a delay in the onset of their therapeutic effect (Gex-Fabry et al., 2004; Machado-Vieira et al., 2008; O'Leary et al., 2015; Smith et al., 2002).”
BackgroundThe relationship between insomnia and major depressive disorder: a chicken and egg situation?
Güleç, M., Özcan, H., Oral, E., Selvı, Y., & Aydın, A. (2012) · Journal of Mood Disorders · doi:10.5455/jmood.20120208025502 · Cited by 12
“Journal of Mood Disorders 2012;2(1):XX-XX ABS TRACT: The relationship between insomnia and major depressive disorder: a chicken and egg situation?”
BackgroundInfluentialVisser, A. K. D., Kleijn, J., van Faassen, M. H. J. R., Dremencov, E., Flik, G., Kema, I. P., den Boer, J. A., van Waarde, A., Dierckx, R., & Bosker, F. J. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.12.006 · Cited by 14
Vieta, E., Bauer, M., Montgomery, S., McIntyre, R. S., Szamosi, J., Earley, W. R., & Eriksson, H. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.052 · Cited by 10
“Current treatment options for major depressive disorder (MDD), including selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs), may be associated with a delay, typically of at least 2 weeks, between the initiation of therapy and onset of improvement in depressive symp…”
BackgroundClegg, A. J., Hill, J. E., Mullin, D. S., Harris, C., Smith, C. J., Lightbody, C. E., Dwan, K., Cooney, G. M., Mead, G. E., & Watkins, C. L. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004366.pub7 · Cited by 12
Early augmentation by using neuromodulation in psychiatric disorder: a kaleidoscopic view
Kar, S. K., & Menon, V. (2021) · CNS Spectrums · doi:10.1017/s1092852921000237 · Cited by 9
Donig, A., & Hautzinger, M. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2021.1888205 · Cited by 9
“life as well as considerable functional impairment and might also often be associated with a significant risk of suicidal acts [28,29].”
BackgroundChen, Y., Shen, M., Liu, X., Xu, J., & Wang, C. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.789524 · Cited by 9
“Antidepressants aiming at these previously defined targets normally require from 3 to 8 weeks to produce a therapeutic response; however, they affect neurotransmitters immediately (Machado-Vieira et al., 2008).”
BackgroundGuo, J. P., Zhou, D., Grimm, S. W., & Bui, K. (2014) · Xenobiotica · doi:10.3109/00498254.2014.966175 · Cited by 10
“However, acute sedative and psychotomimetic side effects limit the clinical use of ketamine (Krystal et al., 1994; Machado-Vieira et al., 2008).”
BackgroundO’Connor, R. M., Pusceddu, M. M., O’Leary, O. F., Savignac, H. M., Bravo, J. A., Yacoubi, M. E., Vaugeois, J., Dinan, T. G., & Cryan, J. F. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.09.017 · Cited by 12
“Despite this ever increasing prevalence, currently available pharmacological agents indicated for the treatment of depression remain inadequate; burdened with a delayed onset of action (weeks-months) (Machado-Vieira et al., 2008), a significant percentage of non-responders (Dinan, 1993; Fava, 2003) and side-effects (B…”
BackgroundSantos¹, L. F. D. S., Behrens, L. M. P., Barbosa, C. P., Ribeiro, C. T., da Rosa, H. T., Somensi, N., Brum, P. O., Silveira, A. K., Rodrigues, M. S., de Oliveira, J., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-03912-3 · Cited by 10
“To the best of our knowledge, CUMS is the most used animal model in preclinical studies of the pathophysiology of depression [29, 53].”
Combinations of dextromethorphan for the treatment of mood disorders - a review of the evidence
Parincu, Z., & Iosifescu, D. V. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2192402 · Cited by 10
Bui, K., Zhou, D., Agbo, F., & Guo, J. P. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.515 · Cited by 8
“However, acute sedative and psychotomimetic side effects limit the clinical use of ketamine.(8,9) Lanicemine was originally developed as an intravenous treatment for stroke and sleep apnea because of neuroprotective and antiepileptic properties demonstrated in early nonclinical studies.”
BackgroundWeisler, R. H., McIntyre, R. S., & Bauer, M. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.846519 · Cited by 8
Nist, A. N., Walsh, S. J., & Shahan, T. A. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06514-4 · Cited by 5
Zannikos, P., Solanki, B., Meulder, M. D., Badorrek, P., Hohlfeld, J. M., & Singh, J. B. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01273-z · Cited by 5
Quevedo, J., Comim, C. M., & Gavioli, E. C. (2009) · Biomarkers in Medicine · doi:10.2217/17520363.3.1.5 · Cited by 6
A New Paradigm Shift in Antidepressant Therapy: From Dual-action to Multitarget-directed Ligands
Rodríguez-Lavado, J., Alarcón‐Espósito, J., Mallea, M., & Lorente, A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220317121551 · Cited by 5
Saleem, U., Iman, S., Ahmad, B., Shah, M. A., Bibi, S., Alqarni, M. A., Khan, M. S., Shah, G. M., Khan, H. Z., Alhasani, R. H., et al. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-00955-0 · Cited by 6
Neurobiology of Monoaminergic Neurotransmission and Antidepressants
Lopez-Munoz, F. J., & Álamo, C. (2013) · Springer eBooks · doi:10.1007/978-81-322-0825-9_23 · Cited by 5
van der Watt, A. S. J., Dalvie, N., & Seedat, S. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114821 · Cited by 4
Kowalczyk, E., Borysowski, J., Ordak, M., Kniotek, M., Radziwoń-Zaleska, M., & Siwek, M. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115730 · Cited by 4
Kronenberg, S. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.47 · Cited by 5
A Special Regenerative Rehabilitation and Genomics Letter: Is There a “Hope” Molecule?
Phillips, C., & Salehi, A. (2016) · Physical Therapy · doi:10.2522/ptj.2016.96.4.581 · Cited by 4
Agomelatine as monotherapy for major depression: an outpatient, open-label study
Pečeňák, J., & Novotny, V. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s49062 · Cited by 5
“Early improvement of depressive symptoms is very desirable because delayed onset of antidepressant treatment is linked with several negative factors, from prolonged social and working dysfunction to increased risk of suicide and additional deleterious neurobiologic changes.(46) In recent years, there has been a growin…”
Etiévant, A., Lambás‐Señas, L., Abrial, E., Betry, C., Haddjeri, N., & Lucas, G. (2011) · Neuropsychiatry · doi:10.2217/npy.11.9 · Cited by 9
Avalos-Moreno, D. A., Cuevas-Carbonell, S. G., Ramírez-Vargas, M. E., Castro‐Sánchez, L., Virgen‐Ortiz, A., Sánchez-Pastor, E. A., Góngora-Alfaro, J. L., Navarro‐Polanco, R. A., Moreno-Galindo, E. G., & Alamilla, J. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116050 · Cited by 3
Effects of zuranolone on next-day simulated driving in healthy adults
Dunbar, J., Morelli, G., Jain, R., Vaudreuil, C., Nandy, I. M., Ona, V. O., Moseley, M. K., Levin, S. N., & Kay, G. G. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06687-6 · Cited by 4
Quiroz, J. A., Chen, G., Drevets, W. C., Henter, I. D., & Manji, H. K. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511980053.004 · Cited by 5
Self-citationCarter, G. L., Sperandei, S., Chitty, K. M., & Page, A. (2021) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12812 · Cited by 3
Iinuma, Y., Nobukawa, S., Nishimura, H., & Takahashi, T. (2022) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc48229.2022.9871057 · Cited by 3
Neurobiological Aspects of Depression: How Do They Affect Neurologic Disorders?
Hečimović, H. (2012) · Wiley eBooks · doi:10.1002/9781118348093.ch2 · Cited by 3
Treating Maternal Depression: Considerations for the Well-Being of the Mother and Child
Brummelte, S. (2018) · Policy Insights from the Behavioral and Brain Sciences · doi:10.1177/2372732217740594 · Cited by 2
Ashrafuzzaman, M., Ji, S. H., Ahn, H., Chung, H. W., Choi, D., Park, J. J., Go, M., Pyo, J. I., Shafioul, A. S. M., Lee, D., et al. (2023) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.12693 · Cited by 2
Tokuda, A., Nagumo, Y., Kajino, K., Iio, K., Sakurai, K., Mizuno, S., Saitoh, A., Saitoh, T., & Nagase, H. (2025) · Neuropsychopharmacology Reports · doi:10.1002/npr2.70059 · Cited by 2
“This delay underscores an urgent need for new antidepressants with fewer adverse effects and faster onset to enhance patient safety and treatment efficacy [4].”
Pharmacological interventions for depression in people with traumatic brain injury
Vattakatuchery, J. J., Lathif, N., Joy, J., Cavanna, A. E., & Rickards, H. E. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010419 · Cited by 3
Kumpula, D. J. (2013) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3x63f · Cited by 2
Fu, Y., Ji, J. L., Shi, S. X., Zhang, H. Y., Lin, G. Z., Zhang, Y. L., Li, X., & Wu, W. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2175998 · Cited by 1
Zhang, L., Bao, D., & Wang, C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116490 · Cited by 1
Yule, A. M., Kim, A., Burns, K., DiSalvo, M., Rao, V., Stone, M., Lanni, S. R., & Wilens, T. E. (2025) · Journal of Mood and Anxiety Disorders · doi:10.1016/j.xjmad.2025.100149 · Cited by 1
“Regarding pharmacotherapy, patients were considered to be treated if at any point in the study period they received a relevant medication at a minimum effective dose for greater than or equal to 4 weeks [19,20].”
Gao, Z., Chen, X., Yu, X., Hu, L., & Gao, C. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122443 · Cited by 2
Kubek, M. J., Domb, A. J., Kubek, D. J., & Veronesi, M. C. (2013) · Advances in delivery science and technology · doi:10.1007/978-1-4614-9434-8_8 · Cited by 1
González-Pinto, A. M. (2020) · Psiquiatría Biológica · doi:10.1016/j.psiq.2020.01.001 · Cited by 3
Li, Q., Chan, W. M., Rudd, J. A., Wang, C. M., Lam, P. Y. H., Wai, M. S. M., Wood, D. M., Dargan, P. I., & Yew, D. T. W. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415816-0.00012-2 · Cited by 2
Abou-Gharbia, M. A., & Childers, W. E. (2010) · Wiley eBooks · doi:10.1002/9783527630035.ch21 · Cited by 1
Ketamine and electroconvulsive therapy pairing in depression and mood disorders
Köse, S., & Çetin, M. (2017) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2017.1332513 · Cited by 3
“of all present antidepressants is delayed onset of action [1].”
BackgroundInvestigating Chronotherapeutic Interventions for the Treatment of Depression
Cunningham, J. E. A. (2018) · TSpace (University of Toronto) · Cited by 2
Treating Depression in Clinical Practice: New Insights on the Multidisciplinary Use of TradozonePreprint
Albert, U., Tomasetti, C., Marra, C., Neviani, F., Pirani, A., Taddeo, D., Zanetti, O. O., & Maina, G. (2023) · Preprints.org · doi:10.20944/preprints202302.0380.v1
Pharmacological and Developmental Aspects on Neuronal Plasticity
Bjartmar, L. (2009) · DiVA (Linkoping University)
Osuman, B. A. (2011) · NVA (Nasjonalt vitenarkiv)
The most common mistakes in the treatment of depression in primary care
Racková, S. (2018) · Medicína pro praxi · doi:10.36290/med.2018.006
Pharmacological Properties of Chromobacterium violaceum Violacein at the Human Serotonin 2C Receptor
Fears, L., Curtis, M., Johnson, T. L., & Fentress, H. M. (2016) · The FASEB Journal · doi:10.1096/fasebj.30.1_supplement.932.1
Pilon, D., Karkare, S. U., Zhdanava, M., Sheehan, J. J., Côté‐Sergent, A., Shah, A., Lopena, O. J., Lefèbvre, P., Joshi, K., & Citrome, L. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.2003673
Begyinah, R. K., Adutwum-Ofosu, K. K., Mensah, J. A., Kwapong, A. A., Appiah, F., Burns, F. B., Amoateng, P., & Kukuia, K. K. E. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4752205
Hosseini, S. M., Shariati, S., Gholyaf, M., Bakhtiari, K., Zamanirafe, M., Ahmadpanah, M., & Mehrpooya, M. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822312474240827051942
Nuevos fármacos para la depresión posparto
Fontanet, A. A., Salinas, N. E., & Asenjo, J. P. (2025) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2024.04.008
Nist, A. N., Walsh, S. J., & Shahan, T. A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06794-y
The Injection of Ghrelin (OXE-103) Improves Subacute Concussion Symptom Burden and Quality of Life
Rippee, M. A., Wyand, M. S., Chen, J., Kirchhoff-Rowald, A., Hunt, S. L., & Bansal, V. (2025) · Neurotrauma Reports · doi:10.1089/neur.2025.0038 · Cited by 1
Neurensin-2 is a negative regulator of CB1 receptor
Ghanem, Y. A., Dorfman-Yahad, L., Hovav, H. C., Agbariya, L., Cohen, A., Yehuda, H., & Umschweif, G. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117382
Esketamine ameliorates depression-like behavior in mice via modulation of the NRG1–ErbB4 pathway
Yu, H., Zhu, Y., Wang, J., He, Y., Li, H., Li, S., Wang, N., Chen, N., Chen, J., Song, H., et al. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1722336
“It swiftly crosses the blood-brain barrier within fi ve minutes of injection, exhibiting prompt and notable antidepressant effects, a short half-life, swift recovery, mild respiratory depression, and minimal psychiatric side effects, garnering signi fi cant attention (4, 5).”
Current Evidence of Acetyl-L-Carnitine Use in Mood Disorders-: A Systematic Review and Meta-Analysis
Kumar, R., Hashempour, Z., Shahriarirad, S., Shahriarirad, R., Hassett, L. C., Singh, B., Croarkin, P. E., Veldić, M., Frye, M. A., & Pagali, S. R. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s586506
Ketamine and Evolving Neuroplasticity
Prabakar, A. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01565-9
Shamabadi, A., Karami, R., Sadati, S., Farahmand, K., Ershadmanesh, M., Moosavi, R., Rahiminejad, F., Ardakani, M. R. K., & Akhondzadeh, S. (2026) · Depression and Anxiety · doi:10.1155/da/5812795
Kallarackal, J., Dyer, B. J., & Huang, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-25214-2_36
Prakash, A., Mahapatra, P., Pattnaik, J. I., Panda, U. K., & Das, S. K. (2026) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_845_25
“[5,6] This temporal gap between treatment initiation and therapeutic response represents one of the most pressing unmet needs in depression management.”
Influential
Metadata
- Authors
- Machado-Vieira, R., Salvadore, G., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-06-15
- Volume
- 69
- Issue
- 6
- Pages
- 946-958
- ISSN
- 0160-6689 (ISSN-L)
- PMC
- PMC2699451
- OpenAlex
- W2000031234
- Cited by
- 195
- References
- 147
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 7 · 2023: 11 · 2022: 8 · 2021: 13 · 2020: 13 · 2019: 9 · 2018: 8 · 2017: 8 · 2016: 7 · 2015: 10 · 2014: 15 · 2013: 13 · 2012: 18
- FWCI
- 8.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health
- National Institute of Mental Health (Z01MH002853, Z01MH002828, Z01MH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- depression, glutamate, sleep, rapid-acting antidepressants, suicidal behavior, treatment latency
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Severity of Illness Index, Time Factors, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.